In September last year, we reported Servier had advanced its emerging neurology pipeline into the clinical trials stage by licensing a drug for the rare genetic disorder Fragile X syndrome
Large-scale, multi-country real-world evidence (RWE) studies—including in Central Nervous System (CNS) indications—have the potential to deliver critical new insights.
Meeting the demand for clinically relevant neurodegenerative treatments requires a paradigm shift in how central nervous system (CNS) clinical trials have been designed and executed.
